Islay Capital Management’s Rani Therapeutics RANI Stock Holding History

Islay Capital Management’s Portfolio RANI Stock Details RANI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.31K	Hold	9,611	–	–	﹤0.01%	185
2026 Q1	$7.06K	Hold	9,611	–	–	﹤0.01%	169
2025 Q4	$13K	Hold	9,611	–	–	0.01%	163
2025 Q3	$4.8K	Hold	9,611	–	–	﹤0.01%	183
2025 Q2	$4.94K	Hold	9,611	–	–	﹤0.01%	166
2025 Q1	$12.1K	Hold	9,611	–	–	0.01%	146
2024 Q4	$13.2K	Hold	9,611	–	–	0.01%	155
2024 Q3	$20.8K	Hold	9,611	–	–	0.01%	147
2024 Q2	$36.5K	Hold	9,611	–	–	0.03%	135
2024 Q1	$29.9K	Hold	9,611	–	–	0.02%	143
2023 Q4	$31.9K	Hold	9,611	–	–	0.02%	151
2023 Q3	$20.9K	Hold	9,611	–	–	0.02%	157
2023 Q2	$39.6K	Hold	9,611	–	–	0.03%	133
2023 Q1	$49.6K	Hold	9,611	–	–	0.05%	131
2022 Q4	$56.7K	Hold	9,611	–	–	0.07%	123
2022 Q3	$92K	Hold	9,611	–	–	0.11%	108
2022 Q2	$99K	Buy	+9,611	New	+$110K	0.1%	134

Other funds holding RANI

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Islay Capital Management's RANI Position: Q2 2026 in Review

Islay Capital Management held its Rani Therapeutics (RANI) position steady in Q2 2026 at 9,611 shares worth $7.31K. The position accounts for ﹤0.01% of the portfolio, ranked #185.

Islay Capital Management first reported a position in RANI in Q2 2022 and has held it in 17 quarters since. The position peaked at $99K in Q2 2022. 68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

Islay Capital Management held 9,611 shares of Rani Therapeutics worth $7.31K as of Q2 2026.
Islay Capital Management left its Rani Therapeutics share count unchanged in Q2 2026.
Rani Therapeutics made up ﹤0.01% of Islay Capital Management's portfolio in Q2 2026, its #185 holding.
Islay Capital Management first reported a position in Rani Therapeutics in Q2 2022 and has held it in 17 quarters since.
Islay Capital Management's Rani Therapeutics position peaked at $99K in Q2 2022.
68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Islay Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.